International Journal of Radiation Oncology * Biology * Physics
Volume 66, Issue 5 , Pages 1328-1334 , 1 December 2006

The impact of axillary lymph nodes removed in staging of node-positive breast carcinoma

  • Bekir Kuru, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Bekir Kuru, M.D., Serdar sokak 45/4, 06170 Yenimahalle, Ankara, Turkey. Tel: (+90) 532-775-5668; Fax: (+90) 312-345-4979
    • ,
  • Mustafa Bozgul, M.D.

Received 5 June 2006 ,Revised 17 July 2006 ,Accepted 17 July 2006.

References 

  1. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–3636
  2. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–187
  3. Hagan MP, Mendenhall NP. Adjuvant therapy after modified radical mastectomy. In:  Bland KI,  Copeland EM editor. The breast: Comprehensive management of benign and malignant diseases. 2nd ed.. Philadelphia, PA: W.B. Saunders Company; 1998;p. 1160–1171
  4. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized trial comparing radical mastectomy and total mastectomy with and without radiation. N Engl J Med. 1985;312:674–681
  5. Axelsson CK, Mouridsen H, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. Eur J Cancer. 1993;28A:1415–1418
  6. Mathiesen O, Carl J, Bonderup O, et al. Axillary sampling and the risk of erroneous staging of breast cancer (Analysis of 960 consecutive patients). Acta Oncol. 1990;29:721–725
  7. Kricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in breast carcinoma. Cancer. 1992;69:2496–2501
  8. Fisher B, Wolmark N, Bauer N, et al. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet. 1981;152:765–772
  9. Somner JEA, Dixon JMJ, Thomas JSJ. Node retrieval in axillary lymph node dissections (Recommendations for a minimum numbers to be confident about node negative status). J Clin Pathol. 2004;57:845–848
  10. Iyer RV, Hanlon A, Fowble B, et al. Accuracy of the extent of axillary nodal positivity related to primary tumor size, number of involved nodes, and number of nodes examined. Int J Radiat Oncol Biol Phys. 2000;47:1177–1183
  11. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569–1583
  12. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–1569
  13. Schaapveld M, Otter R, de Vries EGE, et al. Variability in axillary lymph node dissection for breast cancer. J Surg Oncol. 2004;87:4–12
  14. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer (The value of histological grade in breast cancer. Experience from a large study with long-term follow-up). Histopathology. 1991;19:403–410
  15. Wilking N, Rutqvist LE, Carsten A, et al. Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Acta Oncol. 1992;3:29–35
  16. Willemse PH, Otter R, Schaapveld M, et al. Quality analysis of axillary lymph node dissection in breast cancer patients in the northern part of The Netherlands. [Abstract] Proc Am Soc Clin Oncol. 1999;ASCO annual meeting.
  17. Studer UE, Scherz S, Scheidegger J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastasis. J Urol. 1990;144:243–245
  18. Rosen PP, Lesser ML, Kinne DW, et al. Discontinuous or skip metastases in breast carcinoma. Ann Surg. 1983;197:276–283
  19. Petrik DW, McReady DR, Sawka CA, et al. Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer. J Surg Oncol. 2003;82:84–90
  20. Saha S, Farrar WB, Young DC, et al. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol. 2000;73:134–137
  21. Larson D, Weinstein M, Goldberg I, et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys. 1986;12:1575–1582
  22. Kiel KD, Rademacker AW. Early-stage breast cancer: Arm edema after wide excision and breast irradiation. Radiology. 1996;198:279–283
  23. Suneson BL. Clinical incidence of lymphedema in breast cancer patients in Jonkoping County, Sweden. Eur J Cancer Care. 1996;5:1–12
  24. Edwards TL. Prevalence and aetiology of lymphedema after breast cancer treatment in Southern Tasmania. Aust N Z J Surg. 2000;70:412–418
  25. Ozaslan C, Kuru B. Lymphedema after treatment of breast cancer. Am J Surg. 2004;187:69–72
  26. Tominaga T, Takashima S, Danno M Modified Radical Mastectomy Study Group. Randomized clinical trial comparing level II and III axillary node dissection in addition to mastectomy for breast cancer. Br J Surg. 2003;91:38–43
  27. Joslyn SA, Konety BR. Effect of axillary lymphadenectomy on breast carcinoma survival. Breast Cancer Res Treat. 2005;91:11–18
  28. Vinh-Hung V, Cserni G, Burzykowski T, et al. Effect of the number of uninvolved nodes on survival in early breast cancer. Oncol Reports. 2003;10:363–368
  29. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394–395
  30. Guenther JM. Axillary dissection after unsuccessful sentinel lymphadenectomy for breast cancer. Am Surg. 1999;65:991–994
  31. McMasters KM. The eternally enigmatic axilla: Further controversy about axillary lymph nodes in breast cancer. Ann Oncol. 2003;10:1128–1130
  32. Jatoi I, Hilsenbeck SG, Clark GM, et al. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999;17:2334–2340
  33. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2001;19:602–611
  34. Rodenhuis S, Bontenbal M, Beex LV, et al. Netherlands Working Party on Autologous Transplantation in Solid Tumors High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003;349:7–16
  35. U.S. National Institutes of Health. Adjuvant doxorubicin, cyclophosphamide, and paclitaxel in treating patients with breast cancer. Conditions: Stage I breast cancer; stage II breast cancer; stage IIIA breast cancer; stage IIIC breast cancer; male breast cancer. Available at: http://www.clinicaltrials.gov/ct/show/NCT00070564?order=1. Accessed August 4, 2006.
  36. Kuru B, Camlibel M, Dinc S, et al. Prognostic significance of apex axillary invasion for locoregional recurrence and effect of postmastectomy radiotherapy on overall survival in node positive breast cancer patients. World J Surg. 2004;28:236–241
  37. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst. 2001;93:979–989
  38. Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer? (A meta-analysis). J Clin Oncol. 2000;18:1220–1229
  39. Overgaard M, Hansen PS, Overgaard J, et al. Danish Breast Cancer Cooperative Group 82b Trial Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337:949–955
  40. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomised trial. J Natl Cancer Inst. 2005;97:116–126
  41. Sigurdson ER. Lymph node dissection: Is it diagnostic or therapeutic. J Clin Oncol. 2003;21:965–967

 This study was performed at Ankara Oncology Education and Research Hospital, Ankara, Turkey.

PII: S0360-3016(06)01254-5

doi: 10.1016/j.ijrobp.2006.07.015

International Journal of Radiation Oncology * Biology * Physics
Volume 66, Issue 5 , Pages 1328-1334 , 1 December 2006

Article Tools

* Image Usage & Resolution